Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03800693 · ClinicalTrials.gov registry record · Phase 2

2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers

A Phase 2 study of Malignant Digestive System Neoplasm, sponsored by Emory University.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
3
Study locations

NCT03800693 is a Phase 2 study of Malignant Digestive System Neoplasm that is actively recruiting participants, run by Emory University. The registered enrollment target is 60 participants, below the 685-participant average among 11 other Malignant Digestive System Neoplasm trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03800693, a Phase 2 study of Malignant Digestive System Neoplasm, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
3
Study locations

Study Summary

This phase II trial studies how well giving oxaliplatin over 6 hours works in treating nerve damage in patients with gastrointestinal cancers. Oxaliplatin can cause side effects such as nerve damage that may delay or reduce the dose of oxaliplatin. Giving oxaliplatin over a longer period of time (6 hours) may prevent or delay the development of nerve damage, which may keep patients on standard doses of chemotherapy longer, without having to delay treatment.

Interventions

  • DRUG Fluorouracil
  • DRUG Leucovorin
  • DRUG Oxaliplatin

Study Locations (3)

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University Hospital/Winship Cancer Institute - Atlanta
  • Emory Saint Joseph's Hospital - Atlanta

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2019-03-14
Est. Completion 2026-09-17
Phase Phase 2

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT03800693

The ClinicalTrials.gov registry entry for NCT03800693 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 685-participant average among 11 other Malignant Digestive System Neoplasm trials with a reported enrollment target (91% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Digestive System Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Fluorouracil is the first listed.

NCT03800693 reports 3 study locations spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT03800693 about?

NCT03800693 is a clinical study titled "2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers". This phase II trial studies how well giving oxaliplatin over 6 hours works in treating nerve damage in patients with gastrointestinal cancers. Oxaliplatin can cause side effects such as nerve damage that may delay or reduce the dose of oxaliplatin. Giving oxaliplatin over a longer period of time (6 ...

What is the current status of trial NCT03800693?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2019-03-14. Estimated completion is 2026-09-17.

What conditions does trial NCT03800693 study?

This clinical trial studies the following conditions: Malignant Digestive System Neoplasm.

What interventions are being tested in trial NCT03800693?

The interventions under investigation include: Fluorouracil (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG).

Who is sponsoring clinical trial NCT03800693?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03800693 being conducted?

This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Digestive System Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.